Non-enzymatic glycation mediated structure-function changes in proteins: case of serum albumin

被引:25
作者
Awasthi, Saurabh [1 ]
Saraswathi, N. T. [1 ]
机构
[1] SASTRA Univ, Mol Biophys Lab, Sch Chem & Biotechnol, Thanjavur 613401, Tamil Nadu, India
关键词
TYPE-2; DIABETES-MELLITUS; ESTERASE-LIKE ACTIVITY; NON-ENZYMATIC GLUCOSYLATION; WEIGHT AGGREGATE FORMATION; LENS CRYSTALLIN GLYCATION; DRUG BINDING-SITES; END-PRODUCT AGE; IN-VITRO; LIGAND-BINDING; ACID-BINDING;
D O I
10.1039/c6ra08283a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Albumin, a major plasma protein with extraordinary ligand binding properties, transports various ligands ranging from drugs, hormones, fatty acids, and toxins to different tissues and organs in the body. Albumin can undergo glycation on reacting with circulating reducing sugars, and this modification can occur even more frequently under hyperglycaemic conditions. Glycation is a non-enzymatic reaction of proteins and sugars, which gives rise to the formation of early and advanced glycation end products (AGEs). AGEs are a fundamental factor in the development and progression of severe diabetic complications such as nephropathy, neuropathy, retinopathy and cardiovascular disorders. The pathological impact of AGEs is mainly attributed to the structural modifications of proteins due to their cross-linking properties and the modification of lysine and arginine side chains. Herein, we review the structure-function effects of glycation on albumin, specifically focusing on its drug binding functions. Considering its physiological significance, there is a need to focus current research on determining the structure-function impacts of non-enzymatic glycation on serum albumin.
引用
收藏
页码:90739 / 90753
页数:15
相关论文
共 222 条
[51]   Nutrition and aging skin: sugar and glycation [J].
Danby, F. William .
CLINICS IN DERMATOLOGY, 2010, 28 (04) :409-411
[52]   Diabetes-related mortality - A pediatrician's view [J].
Daneman, D .
DIABETES CARE, 2001, 24 (05) :801-802
[53]  
DUBOISPRESLE N, 1995, MOL PHARMACOL, V47, P647
[54]  
Dufour C., 2005, BIOCHIM BIOPHYS ACTA, V18, P1
[55]   Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: Impact of albumin glycosylation on the binding of teicoplanin to albumin [J].
Enokiya, Tomoyuki ;
Muraki, Yuichi ;
Iwamoto, Takuya ;
Okuda, Masahiro .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 46 (02) :164-168
[56]   Human serum albumin: From bench to bedside [J].
Fanali, Gabriella ;
di Masi, Alessandra ;
Trezza, Viviana ;
Marino, Maria ;
Fasano, Mauro ;
Ascenzi, Paolo .
MOLECULAR ASPECTS OF MEDICINE, 2012, 33 (03) :209-290
[57]   The extraordinary ligand binding properties of human serum albumin [J].
Fasano, M ;
Curry, S ;
Terreno, E ;
Galliano, M ;
Fanali, G ;
Narciso, P ;
Notari, S ;
Ascenzi, P .
IUBMB LIFE, 2005, 57 (12) :787-796
[58]   Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin [J].
Faure, Patrice ;
Wiernsperger, Nicolas ;
Polge, Camille ;
Favier, Alain ;
Mimi, Serge .
CLINICAL SCIENCE, 2008, 114 (3-4) :251-256
[59]  
FIGGE J, 1991, J LAB CLIN MED, V117, P453
[60]   Glycation in diabetic nephropathy [J].
Forbes, Josephine M. ;
Cooper, Mark E. .
AMINO ACIDS, 2012, 42 (04) :1185-1192